

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

As a continuation of the Inside Information notes filed by Grifols on 17 September 2021 and 26 October 2021, Grifols informs about the fulfilment of all the offer conditions with respect to the voluntary tender offer ("**VTO**") launched by Grifols to acquire the remaining ordinary and preferred shares of Biotest AG ("**Biotest**"), conditions which were detailed in the offer document published on 26 October 2021 and which is available at Grifols' web site:

<https://www.grifols.com/documents/3625622/3684838/OFFER-~1.PDF/cb8eca34-2b94-4afe-8615-94f919c12024?t=1635236807904>.

It is foreseen to close the share purchase agreement entered into with Tiancheng International Investment Limited to acquire all the existing share capital of Tiancheng (Germany) Pharmaceutical Holding AG ("**HoldCo**") shortly after the VTO is settled. HoldCo holds approximately an 89.88% stake of the ordinary shares and 1.08% stake of the preferred shares of Biotest.

In Barcelona, on 12 April 2022.

Nuria Martín Barnés
Secretary to the Board of Directors